Drug Trial Radar · NCT06726148
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
280
Planned (sponsor's estimate)
Start
Apr 3, 2025
Primary completion
Sep 25, 2028
Study completion Sep 25, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.
Conditions
- Advanced HR+/HER2- Breast Cancer
- Advanced CCNE1-amplified Solid Tumors
- Extensive-stage Small Cell Lung Cancer
Interventions
ECI830Drug
Experimental
ribociclibDrug
Approved medication
fulvestrantDrug
Approved medication
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: Incidence of dose-limiting toxicities (DLTs)Time frame: 2 years
- Phase I: Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: 2 years
- Phase I: Number of participants with dose interruptions, reductions and discontinuationsTime frame: 2 years
- Phase II: PFS rate at 6 months per local response evaluation criteria in solid tumors (RECIST) v1.1Time frame: 6 months
Locations
33 sites in 16 countries. Site status is shown where the registry gives one.
University of California LA
Los Angeles, California · Recruiting
Florida Cancer Specialists
Fort Myers, Florida · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
WA Uni School Of Med
St Louis, Missouri · Recruiting
Memorial Sloan Kettering
New York, New York · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
MD Anderson Cancer Center Uni of Te
Houston, Texas · Recruiting
Fred Hutch Cancer Research
Seattle, Washington · Recruiting
Novartis Investigative Site
Clayton, Victoria, Australia · Recruiting
Novartis Investigative Site
Melbourne, Victoria, Australia · Recruiting
Novartis Investigative Site
Toronto, Ontario, Canada · Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada · Recruiting
Novartis Investigative Site
Nanjing, Jiangsu, China · Recruiting
Novartis Investigative Site
Xian, Shanxi, China · Recruiting
Novartis Investigative Site
Brno, Czechia · Recruiting
Novartis Investigative Site
Copenhagen, Denmark · Recruiting
Novartis Investigative Site
Odense C, Denmark · Recruiting
Novartis Investigative Site
Bordeaux, France · Recruiting
Novartis Investigative Site
Saint-Herblain, France · Recruiting
Novartis Investigative Site
Heidelberg, Germany · Recruiting
Novartis Investigative Site
Ulm, Germany · Recruiting
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany · Recruiting
Novartis Investigative Site
Haifa, Israel · Recruiting
Novartis Investigative Site
Tel Aviv, Israel · Recruiting
Novartis Investigative Site
Milan, MI, Italy · Recruiting
Novartis Investigative Site
Modena, MO, Italy · Recruiting
Novartis Investigative Site
Chuo Ku, Tokyo, Japan · Recruiting
Novartis Investigative Site
Singapore, Singapore · Recruiting
Novartis Investigative Site
Seoul, Seoul, South Korea · Recruiting
Novartis Investigative Site
Barcelona, Spain · Recruiting
Novartis Investigative Site
Barcelona, Spain · Recruiting
Novartis Investigative Site
Tainan, Taiwan · Recruiting
Novartis Investigative Site
London, Oxford, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.